Industry News
Axon posts loss as revenue slumps
Former share market favorite Axon Instruments has posted after-tax losses of $8.8 million on falling revenues for the half year to June 30. [ + ]
McGauran hopes R&D Start scheme will return in 2003
The return of the Federal government's R&D Start grant scheme may be on the horizon, according to Federal Minister for Science Peter McGauran. [ + ]
Proctor & Gamble to trial Ambri's biosensor
Sydney-based company Ambri has announced that it has entered into an agreement with US consumer products giant Proctor & Gamble. [ + ]
Benitec hires management, gears up to commercialise
Brisbane biotech Benitec has added a managing director and a commercial director to its senior management team, as it prepares to expand its commercialisation activities. [ + ]
New deal suggests FDA approval closer for Gradipore
FDA approval for Sydney-based separation technology company Gradipore has come a step closer, after the signing of a new agreement with Canadian hyperimmune product specialist Cangene. [ + ]
Showcase of scientific research
Some of the dynamic and cutting edge research currently being undertaken at the University of Sydney will be on show late this week and early next week.
[ + ]Analytica rises from the ashes
The Lazarus-like revival of diagnostics company Analytica offers a ray of hope for young Australian biotechs caught in the current funding drought. [ + ]
Norwood Abbey raises $4.13 million
Norwood Abbey has raised $4.13 million in a placement to institutional and professional investors. [ + ]
Solbec hires Bioscience to grow anti-cancer ingredient
Western Australian horticulture company Bioscience has been commissioned by Solbec Pharmaceuticals to set up and run Solbec's horticultural production facility, used to produce its lead anti-cancer compound from Solanum linnaeanum, or devil's apple. [ + ]
Lucre for Bioglobal's LuciLure
Bioglobal has signed an exclusive three-year agreement to market and distribute its LuciLure blowfly trap for sheep protection and landfill markets in Australia and New Zealand. [ + ]
Novogen claims success in heart drug trial
Sydney pharmaceutical company Novogen says the first human clinical trial of its candidate heart-disease therapeutic NV-04 has confirmed the "outstanding potency" it showed in initial trials in laboratory animals. [ + ]
Meditech teams up to market skin cancer treatment
Meditech Research and SkyePharma have completed a commercial pas-de-deux that sees them divide up the Pacific Rim markets for the Solarase, a topical treatment for the pre-cancerous skin condition, actinic or solar keratosis. [ + ]
UK calls for GM animal advisory body
The UK's Agriculture and Environment Biotechnology Commission has called for a new advisory body and development of a strategy to deal with issues relating to genetically modified and cloned animals. [ + ]
Bionomics touts new mouse model, posts loss
A mouse model for inherited epilepsy has been created by Adelaide company Bionomics by 'knocking-in' the human mutation. The model exhibits seizures similar to human epileptic seizures. [ + ]
Autogen wins US patent for Beacon gene
Melbourne biotech Autogen has been granted a US patent for its Beacon gene, and its use as a therapeutic or diagnostic in conditions like obesity, diabetes and energy imbalance. [ + ]
